Soligenix, Inc. (SNGX) Stock Price & Analysis
Soligenix, Inc. (SNGX) fell 0.70% to USD 0.37 as of July 25, 2026 at 06:56 UTC, according to Nexqual real-time market data.
SNGX last closed at USD 0.37; the session ranged USD 0.36–0.38 on volume of 148,224 shares. Market capitalization is $5.50M, with a 52-week range of USD 0.28–6.23 (NCM). Source: Nexqual, July 25, 2026 at 06:56 UTC.
Key Statistics (as of July 25, 2026 at 06:56 UTC)
| Price | USD 0.37 |
|---|---|
| Change | ▼ 0.70% (down) |
| Previous Close | USD 0.37 |
| Open | USD 0.37 |
| Day Range | USD 0.36 – 0.38 |
| 52-Week Range | USD 0.28 – 6.23 |
| Volume | 148,224 shares |
| Market Cap | $5.50M |
| Exchange | NCM |
Technical Analysis (SNGX)
Nexqual's technical model rates SNGX "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:56 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.16 (neutral) |
| vs SMA50 | Below (USD 0.44) |
| MACD | -0.03 (negative) |
Analyst Ratings (SNGX)
Wall Street analysts rate SNGX "None" based on 2 analysts, with a mean price target of USD 1.75 (range USD 1.5–2), per Nexqual as of July 25, 2026 at 06:56 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 1.75 |
| High Target | USD 2 |
| Low Target | USD 1.5 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (SNGX)
| EPS Estimate | USD -0.09 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.28 vs est -0.24 ▼ miss |
| 2025-09-30 | USD -0.58 vs est -0.48 ▼ miss |
| 2025-06-30 | USD -0.82 vs est -1.05 ▲ beat |
Source: Nexqual, July 25, 2026 at 06:56 UTC.
Financials & Fundamentals (SNGX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -326.87% |
| Debt / Equity | 10.7 |
| Current Ratio | 1.81 |
| Total Cash | $6.03M |
| Total Debt | $330,660 |
| Free Cash Flow | $-7.25M |
Source: Nexqual, July 25, 2026 at 06:56 UTC.
Financial Health Score (SNGX)
Nexqual rates Soligenix, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:56 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $6M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$11M |
| Efficiency | Critical — ROE -327%, ROA -99.7% |
Ownership (SNGX)
| Insider Ownership | +6.74% |
|---|---|
| Institutional Ownership | +5.33% |
| Shares Outstanding | 14.82M |
| Float | 14.72M |
| Short % of Float | +3.26% |
Source: Nexqual, July 25, 2026 at 06:56 UTC.
Leadership (SNGX)
Soligenix, Inc. is led by Christopher J. Schaber (age 59), Chairman of the Board of Directors, CEO & President, per Nexqual as of July 25, 2026 at 06:56 UTC.
| Chairman of the Board of Directors, CEO & President | Christopher J. Schaber (age 59) |
|---|---|
| Senior VP, CFO & Corporate Secretary | Jonathan L. Guarino CPA, CGMA (age 52) |
| Senior VP & Chief Scientific Officer | Oreola Donini (age 53) |
Major Backers & Investors (SNGX)
Notable institutional backers of Soligenix, Inc. include Fidelity, according to Nexqual as of July 25, 2026 at 06:56 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.46% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.79% |
| Geode Capital | 0.55% |
Source: Nexqual, July 25, 2026 at 06:56 UTC.
From Soligenix, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States.
- The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHIO | Phio Pharmaceuticals Corp. | USD 1.04 | ▼ 1.89% |
| MBRX | Moleculin Biotech, Inc. | USD 2.12 | ▲ 0.95% |
| RKTO | Rocket One Inc. | USD 0.79 | ▼ 4.35% |
| SNOA | Sonoma Pharmaceuticals, Inc. | USD 1.14 | ▼ 1.72% |
| TENX | Tenax Therapeutics, Inc. | USD 14.53 | ▼ 1.76% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:56 UTC. This page is informational and not investment advice.